Welcome to our dedicated page for Hcw Biologics SEC filings (Ticker: HCWB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HCW Biologics Inc. filings document a clinical-stage biopharmaceutical issuer developing fusion immunotherapeutics through the TOBI and TRBC platforms. Its SEC records include 8-K reports for operating results, clinical and regulatory program updates, material agreements, licensing activity and Nasdaq-related corporate events, along with registration statements covering securities offerings and related capital-structure disclosures.
HCWB proxy and governance filings describe annual meeting matters, shareholder voting procedures and bylaw amendments, including quorum provisions. The company’s formal disclosures also address product-candidate development, financial condition, emerging growth company status, risk factors, ownership and governance controls relevant to its public-company reporting profile.
HCW Biologics Inc. filed Amendment No. 1 to its Registration Statement on Form S-1 as an exhibits-only update. The amendment adds and organizes legal, governance, financing, warrant, equity incentive, and related agreements as exhibits, along with opinion letters, consents, and Inline XBRL data files.
The company states that the remainder of the S-1 registration statement is unchanged and therefore omitted from this amendment. The filing is signed by Founder and Chief Executive Officer Hing C. Wong and other directors and officers, confirming authorization of this administrative update.
HCW Biologics Inc. reported positive preliminary human data from the first two dose cohorts of its dose-escalating Phase 1 trial of HCW9302, an IL-2 based fusion immunotherapeutic, in patients with alopecia areata. All three participants in the second cohort, who received a single 3 micrograms/kg subcutaneous dose, showed at least a 25% reduction in Severity of Alopecia Tool scores at four and/or nine weeks.
The treatment was well tolerated with no dose-limiting toxicities, and no reported capillary leak, cytokine release syndrome, or increased blood eosinophil counts; adverse events were mild, self-limiting, and mainly injection-site reactions. The study is designed to treat up to 30 patients and aims to define a recommended Phase 2 dose by year-end 2026, after which the company may pursue multi-dose studies in alopecia areata and other autoimmune and inflammatory dermatologic indications.
HCW Biologics Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders voted on five proposals, including the election of two directors. Lisa M. Giles received 1,127,580 votes for and 230,984 withheld, with 1,189,957 broker non-votes. Rick S. Greene received 1,128,039 votes for and 230,525 withheld, with the same broker non-votes. Four additional proposals each received more votes for than against, with for votes ranging from about 1.08 million to 2.54 million, indicating generally supportive voting outcomes.
HCW Biologics Inc. has filed an S-1 to register the resale of up to 5,693,950 shares of common stock issued or issuable from a May 2026 private placement (the PIPE Transaction). These shares include stock already issued plus shares underlying pre-funded warrants and May 2026 common warrants.
The company previously raised approximately $4.0 million in gross proceeds from selling 2,846,975 units at $1.405 per unit, each unit including one share or pre-funded warrant and one common warrant. HCW Biologics will not receive proceeds from selling stockholders’ resales, but could receive up to about $3.6 million if the May 2026 common warrants are exercised for cash.
The filing highlights HCW Biologics’ clinical-stage immunotherapy pipeline, commercial-ready cell-therapy reagents, and its status as an emerging growth and smaller reporting company. It also describes Nasdaq bid-price compliance requirements, potential reverse stock split plans, material weaknesses in internal control over financial reporting, and the dilution and volatility risks tied to warrant exercises and additional equity issuance.
HCW Biologics Inc. received a decision from a Nasdaq Hearings Panel granting more time to regain compliance with Nasdaq’s minimum bid price requirement. The company had previously fallen below the $1 per share minimum bid price under Nasdaq Listing Rule 5550(a)(2) after already completing a 1-for-40 reverse stock split on April 11, 2025.
The Panel is allowing the company to remain listed if it achieves a bid price of at least $1 per share for twenty consecutive trading days on or before July 29, 2026. The Panel indicated that if the company again becomes deficient with the bid price rule before September 22, 2026, it will be immediately delisted.
If HCW Biologics satisfies the conditions and regains compliance, the Panel intends to place the company under a Discretionary Panel Monitor for an additional one-year period, adding ongoing oversight of its listing status.
HCW Biologics Inc. director and Chief Executive Officer Hing C. Wong reported significant personal purchases of the company’s securities. On May 22, he bought 113,879 shares of Common Stock at $1.405 per share and acquired Common Stock Purchase Warrants for another 113,879 underlying shares with a $1.28 exercise price, both directly from the issuer in a private placement. Following these transactions, he directly owns 615,790 shares of Common Stock and 118,110 warrants, increasing his overall economic exposure to the company.
HCW Biologics Inc. director T. Scott Garrett, through an LLC, reported net buying activity in both common shares and warrants. The LLC acquired 177,936 shares of common stock at $1.405 per share in a private placement directly from the issuer, which the footnote states is exempt from Section 16(b) under Rule 16b-3(d). Following this transaction, indirect holdings of common stock rose to 203,441 shares. The LLC also acquired 177,936 Common Stock Purchase Warrants with an exercise price of $1.28 per share, expiring on November 22, 2031, increasing indirect warrant holdings to 180,628. In total, the filing shows 355,872 shares’ worth of net buy-side exposure added across stock and warrants.
HCW Biologics Inc. Chief Financial Officer Rebecca Byam bought additional equity in the company on May 22, 2026. She purchased 14,235 shares of common stock at an average price of $1.405 per share, increasing her direct common stock holdings to 57,245 shares.
Byam also acquired a Common Stock Purchase Warrant for 14,235 underlying shares with a conversion price of $1.28 per share, expiring on November 22, 2031, bringing her directly held warrants to 18,466. According to the filing, these securities were purchased directly from the issuer in a private placement exempt from Section 16(b) under Rule 16b-3(d).
HCW Biologics Inc. terminated its exclusive worldwide license with Wugen Inc. for ex vivo rights to its HCW9206 and HCW9201 molecules and regained full ex vivo rights to both reagents. The company acquired these rights for no cost and retained the upfront license consideration, including 2.2 million shares of Wugen common stock.
HCW Biologics believes recent peer-reviewed data suggest HCW9206 may help manufacture more persistent, functional CAR-T cells and memory-like NK cells, potentially lowering production costs. The company plans to commercialize these reagents through partnerships with CAR-T and NK-cell therapy developers and manufacturers.